The Context
Latinos represent 19 percent of the U.S. population but only 1 percent of clinical trial participants. The gap creates data voids in drug efficacy and safety for the fastest-growing demographic, putting pharma companies at regulatory and market risk.
The Takeaway
Expect proxy advisors to press boards on trial-diversity metrics within two cycles. Companies without Latino-enrollment infrastructure face slower FDA pathways and weaker commercial launch data in key growth markets.
Source: Prnewswire